The US Food and Drug Administration (FDA) has cleared Fortini™, a formula meant for the nutritional needs of term infants with failure to thrive.
Following a review by the US Food and Drug Administration, the infant nutrition product Fortini™ by Nutricia is meant to be used under medical supervision and will be available to clinicians and registered dieticians by the end of September 2021.1 The formula is meant to support catch-up growth in term infants with growth failure or who are at risk of it as well as those who require more energy or have fluid restrictions.
The formula can be used in infants and toddlers up to age 18 months. The formula has 30 calories per fluid ounce and is the first created to feed infants with undernutrition or failure to thrive. The benefits of the Fortini™ have been supported by 7 clinical trials and a retrospective chart review. In those clinical trials, the formula was shown to be well tolerated by infants and toddlers. To achieve higher caloric density previously, clinicians have often had to recommend special recipes to parents that either involved increased amounts of powdered formula or liquid fats, which carried a risk of mixing errors, unbalanced nutrition, and poor tolerance of the over-concentration of formula.
Nutricia hopes to have the formula available for recommendation to families who qualify for either Medicaid or the Special Supplemental Nutrition Program for Women, Infants, and Children within the year following the product’s launch.
Reference
1. Nutricia. Fortini™ infant formula clears FDA review; energy- and nutrient-dense formula aims to set new standard in US to support growth in infants with, or at risk of, failure to thrive. Published September 23, 2021. Accessed September 29, 2021. https://www.prnewswire.com/news-releases/fortini-infant-formula-clears-fda-review-energy--and-nutrient-dense-formula-aims-to-set-new-standard-in-us-to-support-growth-in-infants-with-or-at-risk-of-failure-to-thrive-301381341.html
This article was originally posted on Contemporary Pediatrics®.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Improved maternal cardiac arrest management reported from Obstetric Life Support training
November 19th 2024A study found that Obstetric Life Support education significantly improves health care providers' readiness and outcomes in maternal cardiac arrest management, advocating for broader implementation.
Read More